PAMU
ALXN

Pictet Asset Management (UK)’s Alexion Pharmaceuticals ALXN Stock Holding History

Pictet Asset Management (UK)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$180M Sell
982,218
-582,521
-37% -$100M 0.2% 144
2021
Q1 		$239M Sell
1,564,739
-383,611
-20% -$59.3M 0.29% 101
2020
Q4 		$304M Buy
1,948,350
+134,303
+7% +$17.3M 0.4% 66
2020
Q3 		$208M Sell
1,814,047
-77,280
-4% -$8.34M 0.32% 91
2020
Q2 		$212M Buy
1,891,327
+733,740
+63% +$77.9M 0.37% 79
2020
Q1 		$104M Buy
1,157,587
+328,356
+40% +$32.2M 0.22% 131
2019
Q4 		$89.7M Sell
829,231
-96,535
-10% -$10.3M 0.16% 171
2019
Q3 		$90.7M Sell
925,766
-674,260
-42% -$76M 0.19% 145
2019
Q2 		$210M Sell
1,600,026
-248,438
-13% -$32M 0.45% 54
2019
Q1 		$250M Buy
1,848,464
+127,040
+7% +$15.8M 0.55% 32
2018
Q4 		$168K Buy
1,721,424
+27,997
+2% +$3.31M 0.42% 63
2018
Q3 		$235M Sell
1,693,427
-6,414
-0.4% -$805K 0.5% 43
2018
Q2 		$211M Buy
1,699,841
+127,840
+8% +$14.9M 0.5% 46
2018
Q1 		$175M Buy
1,572,001
+251,811
+19% +$30.1M 0.43% 60
2017
Q4 		$158M Buy
1,320,190
+193,915
+17% +$23.6M 0.41% 65
2017
Q3 		$158M Buy
1,126,275
+358,695
+47% +$48.7M 0.45% 55
2017
Q2 		$75.2M Sell
767,580
-35,286
-4% -$4.11M 0.23% 136
2017
Q1 		$97.3M Buy
802,866
+23,555
+3% +$3.04M 0.32% 90
2016
Q4 		$95.3M Buy
779,311
+39,303
+5% +$4.81M 0.35% 77
2016
Q3 		$90.7M Buy
740,008
+45,889
+7% +$5.91M 0.34% 80
2016
Q2 		$105M Buy
694,119
+359,851
+108% +$51.1M 0.41% 69
2016
Q1 		$47.1M Buy
334,268
+279
+0.1% +$41K 0.21% 131
2015
Q4 		$63.7M Sell
333,989
-25,097
-7% -$4.38M 0.27% 107
2015
Q3 		$56.2M Buy
359,086
+7,835
+2% +$1.43M 0.25% 111
2015
Q2 		$69.4M Buy
351,251
+98,956
+39% +$17.1M 0.28% 90
2015
Q1 		$42.7M Buy
252,295
+22,181
+10% +$4.01M 0.18% 157
2014
Q4 		$42.6M Buy
230,114
+61,706
+37% +$11.4M 0.19% 141
2014
Q3 		$27.9M Sell
168,408
-18,200
-10% -$2.99M 0.13% 190
2014
Q2 		$29.2M Buy
186,608
+15,200
+9% +$2.4M 0.14% 181
2014
Q1 		$26.1M Sell
171,408
-1,300
-0.8% -$207K 0.13% 182
2013
Q4 		$23M Sell
172,708
-12,700
-7% -$1.52M 0.12% 202
2013
Q3 		$21.5M Sell
185,408
-26,600
-13% -$2.92M 0.12% 197
2013
Q2 		$19.6M Buy
+212,008
New +$20.4M 0.11% 198

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Pictet Asset Management (UK)'s ALXN Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Alexion Pharmaceuticals (ALXN) stake by 37% in Q2 2021, selling an estimated $100M and leaving 982,218 shares worth $180M. The position accounts for 0.2% of the portfolio, ranked #144.

Pictet Asset Management (UK) first reported a position in ALXN in Q2 2013 and has held it in 33 quarters since. The position peaked at $304M in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Pictet Asset Management (UK) held 982,218 shares of Alexion Pharmaceuticals worth $180M as of Q2 2021.
  • Pictet Asset Management (UK) sold 582,521 Alexion Pharmaceuticals shares in Q2 2021, an estimated $100M.
  • Alexion Pharmaceuticals made up 0.2% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #144 holding.
  • Pictet Asset Management (UK) first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
  • Pictet Asset Management (UK)'s Alexion Pharmaceuticals position peaked at $304M in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.